Home » electroCore Snags New Use Indication for Portable Migraine Therapy Technology
electroCore Snags New Use Indication for Portable Migraine Therapy Technology
Bioelectronic medicine company electroCore achieved 510(k) clearance from the FDA for a new use indication on its gammaCore therapy technology.
The new clearance allows for the noninvasive neuromodulation treatment to be used for treating acute migraine-associated pain in adult patients. The FDA previously cleared gammaCore for treating pain associated with adult episodic cluster headache.
Self-administered treatment can be delivered through a hand-held unit designed to provide mild electric stimulation to the vagus nerves through a patient’s skin.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May